Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.
Sarmati L, Nicastri E, Uccella I, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S, Andreoni M. Sarmati L, et al. Among authors: vella s. J Clin Microbiol. 2003 Apr;41(4):1760-2. doi: 10.1128/JCM.41.4.1760-1762.2003. J Clin Microbiol. 2003. PMID: 12682180 Free PMC article.
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.
Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Montano M, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. Nicastri E, et al. Among authors: vella s. J Clin Microbiol. 2003 Jul;41(7):3007-12. doi: 10.1128/JCM.41.7.3007-3012.2003. J Clin Microbiol. 2003. PMID: 12843034 Free PMC article. Clinical Trial.
Non-B HIV type 1 subtypes: replicative capacity and response to antiretroviral therapy.
Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Montano M, Buonomini AR, Galluzzo C, Vullo V, Concia E, Vella S, Andreoni M. Nicastri E, et al. Among authors: vella s. AIDS Res Hum Retroviruses. 2004 Aug;20(8):816-8. doi: 10.1089/0889222041725271. AIDS Res Hum Retroviruses. 2004. PMID: 15320985 No abstract available.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Among authors: vella s. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
595 results